BMJ Open

Patient-reported burden of dry eye disease in the UK: a cross-sectional web-based survey

Parwez Hossain,1,2 Csaba Siffel,3,4 Corey Joseph,3 Juliette Meunier,5,6 Jessica T. Markowitz,5,6 Reza Dana7

ABSTRACT

Objectives To compare sociodemographics and vision-related quality of life (QoL) of individuals with or without dry eye disease (DED); and to explore the impact of DED symptom severity on visual function, activity limitations and work productivity.

Design Cross-sectional web-based survey.

Setting General UK population.

Participants Adults ≥18 years with (N=1002) or without (N=1003) self-reported DED recruited through email and screened.

Main outcome measures All participants completed the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25), with six additional questions (items A3–A8), and the EuroQol 5 dimensions 5 levels. DED participants also completed Impact of Dry Eye on Everyday Life questionnaire, 5-item Dry Eye Questionnaire and the Standardised Patient Evaluation of Eye Dryness questionnaire along with the Ocular Comfort Index, Work Productivity and Activity Impairment and the Eye Dryness Score (EDS), a Visual Analogue Scale.

Results Baseline demographic and clinical characteristics were similar in participants with versus without DED (mean age, 55.2 vs 55.0 years; 61.8% vs 61.0% women, respectively) based on recruitment targets. Scores were derived from NEI VFQ-25 using the new 28-item revised VFQ (VFQ-28R) scoring. Mean (SD) VFQ-28R scores were lower in participants with versus without DED, indicating worse functioning (activity limitations, 73.3 (12.3) vs 84.4 (12.3); socioemotional functioning, 75.3 (21.5) vs 90.3 (16.2); total score, 71.6 (12.8) vs 83.6 (12.6)). Higher percentages of problems/ability to do activities were observed among those with versus without DED. The impact of DED on visual function was worse for participants with more severe DED symptoms, as assessed by EDS. In addition, a higher EDS was associated with worse symptoms on common DED scales and a worse impact on work productivity.

Conclusions DED symptoms were associated with negative effects on visual function, activities and work productivity, whereas worse DED symptoms had a greater impact on vision-related QoL and work productivity.

INTRODUCTION

Dry eye disease (DED) is a commonly occurring ocular condition and a frequent reason for patients to seek medical eye care.1,2 Global DED prevalence is estimated to range from 5% to 50%,2 with estimates in Europe ranging from 10% to 30%.3,4 In a female cohort in the UK (n=3824; mean age, 57.1 years), the overall prevalence of DED was 9.6% (defined as diagnosis by a clinician and use of artificial tears) and the prevalence of reported symptoms of DED in the previous 3 months was 20.8%.4 Prevalence of DED in the UK is higher in women compared with men and increases with age, with the majority of individuals with DED aged >50 years.1,6,12

DED is a major cause for prescribing in primary medical care in the National Health Service in England. In 2014, over 6.4 million prescription items for DED (ie, artificial tears, ocular lubricants and astringents) were dispensed in the community at a cost of more than £27 million to the National Health Service.7 DED can impact health-related and vision-related quality of life (QoL), with affected patients showing greater functional...
improvement associated with physical fatigue, pain, depression, total symptom burden and QoL. Moreover, patients are more likely to experience problems with reading, television and computer use, driving and performing professional work. In addition, DED was associated with approximately 30% impairment in workplace performance, work productivity and non-job-related activities in a prospective cross-sectional study. In a systematic literature search supplemented with information from interviews of ophthalmologists, the annual healthcare costs for 1000 patients with DED who were managed by ophthalmologists in the UK were estimated to be US$1.10 million (2003/2004 prices), with almost one-half of the total attributed to prescription drug costs. Some patients suffering from DED self-treat their symptoms with over-the-counter artificial tears or are treated by general practitioners/optometrists/pharmacists; thus, annual costs could be higher as only reimbursed treatments prescribed by ophthalmologists were captured in this estimate. Given the influence of DED on QoL and healthcare costs, and the minimal published data in the UK, this study was performed to document the burden of DED among adults in the UK. We conducted an online survey and compared the demographics and overall QoL between those with and without DED; evaluated the severity of symptoms and their impact on vision-related QoL and work productivity; assessed the behaviours for seeking care and adhering to treatment and assessed the use of medications for DED.

METHODS

This was a cross-sectional, web-based survey of individuals in the UK with and without DED. Survey participants were ≥18 years of age; resided in the UK at the time of survey completion; spoke, read and understood English and had a self-reported diagnosis of DED or symptoms of DED (for those in the group with DED).
These items were part of the development of the NEI VFQ and, thus, have been validated. The DED survey included the following assessments: symptom severity/frequency Visual Analogue Scale (VAS), Ocular Comfort Index (OCI), Work Productivity and Activity Impairment (WPAI) questionnaire, treatment and resource utilisation, treatment satisfaction and treatment compliance and discontinuation. In addition, participants assigned to survey A completed the Impact of Dry Eye on Everyday Life (IDEEL) questionnaire, and those assigned to survey B completed the 5-item Dry Eye Questionnaire (DEQ-5) and the Standardised Patient Evaluation of Eye Dryness (SPEED) questionnaire. Participants had to complete all questions; missing data were not allowed.

Participants were compensated by the marketing agency that recruited them and fielded the survey; the costs were reimbursed by the study sponsor. Participants were enrolled in a panel where they could earn ‘panel points’ for participation in surveys and were compensated with these ‘panel points’, which also varied based on participant’s tenure in the panel.

Participants with DED were grouped according to DED severity using the Eye Dryness Score (EDS) VAS (0–100; 0=no discomfort, 100=maximal discomfort), which was developed in conjunction with clinical trials conducted in patients with DED. Group 1 was defined as participants with DED and EDS<40; group 2, 40≤EDS<60 and group 3, EDS≥60. Eye dryness is an important symptom of DED that many participants felt was the most relevant.

The EDS identifies the severity of this essential part of DED. Scores from all questionnaires were calculated for each DED severity group; scores from the NEI VFQ-25 were calculated using the new 28-item revised VFQ (VFQ-28R) scoring.

Table 1 includes a brief description of each of the outcome variables included in the survey.

<table>
<thead>
<tr>
<th>Table 1 Outcome variables</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assessment</strong></td>
</tr>
<tr>
<td>VFO-28R</td>
</tr>
<tr>
<td>EQ-5D-5L</td>
</tr>
<tr>
<td>OCI</td>
</tr>
<tr>
<td>WPAI</td>
</tr>
<tr>
<td>IDEEL</td>
</tr>
<tr>
<td>DEQ-5</td>
</tr>
<tr>
<td>SPEED</td>
</tr>
</tbody>
</table>

DED, dry eye disease; DEQ-5, 5-item Dry Eye Questionnaire; EQ-5D-5L, EuroQol 5 dimensions 5 levels; IDEEL, Impact of Dry Eye on Everyday Life; OCI, Ocular Comfort Index; SPEED, Standardised Patient Evaluation of Eye Dryness; NEI VFQ-25, 25-item National Eye Institute Visual Function Questionnaire; VFQ-28R, 28-item revised Visual Function Questionnaire; WPAI, Work Productivity and Activity Impairment.
Identifiable participant data were anonymised prior to analysis. Analyses included descriptions of the following: (1) sociodemographic, diagnosis and medical history data for participants with and without DED, (2) VFQ-28R items with domain scores and EQ-5D-5L for participants with and without DED and (3) overall DED-related burden items and scores from surveys A and B and by EDS severity. No hypothesis was formulated; therefore, no inferential statistics were performed.

Patient and public involvement
This research was done without patient involvement. Patients were not invited to comment on the study design and were not consulted to develop patient relevant outcomes or interpret the results. Patients were not invited to contribute to the writing or editing of this document for readability or accuracy. There are no plans to disseminate the results of the research directly to study participants.

RESULTS
Demographics
Baseline demographic characteristics of participants with DED (N=1002; survey A, n=500; survey B, n=502) and without DED (N=1003) were well balanced based on recruitment targets (table 2). There were 761 participants who started the survey but did not complete it.

More than 80% of survey respondents in either cohort reported the use of digital screens or daily activities such as reading. Other daily environmental factors associated with DED were reported more frequently by participants with versus without DED (ie, air conditioning/recirculated air, 25.1% vs 15.4%; wind or moving air, 32.3% vs 12.3%; forced air/heat, 17.6% vs 8.4%; polluted air, 13.5% vs 7.6%; low humidity, 15.0% vs 5.8%). The most commonly reported medical conditions from the screener form in participants with DED (other than DED) were arthritis (38.1%), hearing loss (24.5%), irritable bowel disease (23.2%) and asthma (16.9%). The most common medical conditions in participants without DED were arthritis (20.9%), asthma (10.4%), hearing loss (9.4%) and irritable bowel disease (8.9%).

Patients with DED were grouped according to severity based on EDS VAS: group 1 (EDS<40), n=534 (53.3%); group 2 (40≤EDS<60), n=218 (21.8%) and group 3 (EDS≥60), n=250 (25.0%). Table 3 includes diagnosis and medical history data for participants with a self-reported diagnosis of DED. Participants with more severe DED were more likely to be diagnosed and treated by a healthcare professional (44.8% in group 1 vs 75.2% in group 3). Approximately half of the healthcare professionals were ophthalmologists (eye doctors), and the rest were primary care doctors or other kind of healthcare professionals.

Comparison of scores between participants with and without DED
Mean (SD) VFQ-28R activity limitations scores, socioemotional functioning scores and total scores reflect good visual functioning in participants without DED, while participants with DED had worse visual functioning (figure 2).

The responses on the EQ-5D-5L showed higher proportions of participants with DED who had problems with mobility, self-care and usual activities; more pain and/or discomfort and more anxiety and/or depression (figure 3).

Vision-related QoL, health status and work productivity of participants with DED
The highest mean (SD) VAS scores for 24-hour DED symptoms were for eye dryness (37.9 (29.3)), tired eyes (37.6 (29.2)) and eye discomfort (32.6 (28.2)). For the scales other than the EDS, mean VAS scores for DED symptoms increased as the severity assessed by the EDS increased.

Symptom severity determined by EDS was associated with severity on common DED instruments, such as the OCI. The mean (SD) overall OCI score for participants with DED was 30.3 (14.1) and increased as the severity of DED increased, as shown in figure 4. The same trend was observed with DEQ-5 and SPEED. Mean (SD) DEQ-5 total score was 8.9 (3.6) for group 1, 11.1 (2.7) for group 2 and 13.4 (3.5) for group 3, indicating a higher severity of DED with increasing DEQ-5 scores. For SPEED, the total mean (SD) scores for participants with DED were 9.6 (5.2) in group 1, 11.9 (5.6) in group 2 and 15.6 (5.1) in group 3. The increasing mean score for SPEED indicated more frequent and/or worsening symptoms as DED severity increased.

All mean (SD) VFQ-28R scores (activity limitations, socioemotional functioning and total) globally decreased
as the severity of DED increased, indicating worsening visual function as DED severity increased (figure 5).

Mean (SD) EQ-5D index scores decreased as DED severity increased, reflecting worsening health status in participants with DED and the highest EDS (group 1, 0.77 (0.23); group 2, 0.70 (0.24); group 3, 0.67 (0.26)). In addition, the percentage of participants reporting problems with each EQ-5D item rose with increasing DED severity (figure 6).

WPAI scores increased with worsening DED severity for ‘percent activity impairment due to problem’. However, mean scores for ‘percent impairment while working due to a problem’, ‘percent overall work impairment due to problem’ and ‘percent work time missed due to problem’ increased from group 1 to group 2, but the mean scores were similar or decreased from group 2 to group 3 (figure 7).

For the IDEEL scores of participants with DED stratified by severity group, greater emotional impact, greater impact on daily activities, greater symptom bother and lower satisfaction with treatment effectiveness were associated with increasing EDS scores. In addition, a greater impact on work and more treatment-related bother were observed with a higher DED severity, though the difference between groups 2 and 3 was not as well defined.

**DISCUSSION**

Previous studies have shown an association between DED and reduced health-related and vision-related QoL. The present study demonstrates that this association is consistent in a population of participants with DED from the UK. Dry eye symptoms were related to a negative impact on daily activities, socioemotional functioning and general health status among participants from a large general population sample in the UK. Increased DED symptom severity was associated with a greater impact on activities, socioemotional functioning and work productivity.

While causal associations cannot be elucidated in this cross-sectional study, problems with mobility, as assessed by the EQ-5D-5L, occurred more often in participants with DED than in participants without DED (36% of participants reported having either slight, moderate,

---

**Table 3** Participants with DED: diagnosis and medical history

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group 1</th>
<th>Group 2</th>
<th>Group 3</th>
<th>Participants with DED</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EDS&lt;40</td>
<td>40≤EDS&lt;60</td>
<td>EDS≥60</td>
<td>N=1002</td>
</tr>
<tr>
<td>Diagnosed by HCP, n (%)</td>
<td>239 (44.8)</td>
<td>124 (66.9)</td>
<td>188 (75.2)</td>
<td>551 (55.0)</td>
</tr>
<tr>
<td>Mean (SD) time since diagnosis of DED, years</td>
<td>6.58 (8.09)</td>
<td>6.32 (7.87)</td>
<td>6.74 (7.20)</td>
<td>6.58 (7.74)</td>
</tr>
<tr>
<td>HCP who diagnosed DED, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye doctor</td>
<td>112 (46.9)</td>
<td>74 (59.7)</td>
<td>105 (55.9)</td>
<td>291 (52.8)</td>
</tr>
<tr>
<td>Primary care doctor</td>
<td>69 (28.9)</td>
<td>31 (25.0)</td>
<td>52 (27.7)</td>
<td>152 (27.6)</td>
</tr>
<tr>
<td>Other</td>
<td>46 (19.2)</td>
<td>14 (11.3)</td>
<td>25 (13.3)</td>
<td>85 (15.4)</td>
</tr>
<tr>
<td>Nurse</td>
<td>6 (2.5)</td>
<td>2 (1.6)</td>
<td>6 (3.2)</td>
<td>14 (2.5)</td>
</tr>
<tr>
<td>Pharmacist</td>
<td>6 (2.5)</td>
<td>3 (2.4)</td>
<td>0</td>
<td>9 (1.6)</td>
</tr>
<tr>
<td>Eye-related conditions, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cataracts</td>
<td>73 (13.7)</td>
<td>37 (17.0)</td>
<td>46 (18.4)</td>
<td>156 (15.6)</td>
</tr>
<tr>
<td>Blepharitis</td>
<td>40 (7.5)</td>
<td>28 (12.8)</td>
<td>39 (15.6)</td>
<td>107 (10.7)</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>35 (6.6)</td>
<td>16 (7.3)</td>
<td>29 (11.6)</td>
<td>80 (8.0)</td>
</tr>
<tr>
<td>Macular degeneration</td>
<td>16 (3.0)</td>
<td>7 (3.2)</td>
<td>16 (6.4)</td>
<td>39 (3.9)</td>
</tr>
<tr>
<td>Diabetic retinopathy</td>
<td>19 (3.6)</td>
<td>6 (2.8)</td>
<td>9 (3.6)</td>
<td>34 (3.4)</td>
</tr>
<tr>
<td>Meibomian gland dysfunction</td>
<td>10 (1.9)</td>
<td>9 (4.1)</td>
<td>13 (5.2)</td>
<td>32 (3.2)</td>
</tr>
<tr>
<td>Sjögren’s syndrome</td>
<td>5 (0.9)</td>
<td>9 (4.1)</td>
<td>18 (7.2)</td>
<td>32 (3.2)</td>
</tr>
<tr>
<td>Uveitis</td>
<td>6 (1.1)</td>
<td>7 (3.2)</td>
<td>13 (5.2)</td>
<td>26 (2.6)</td>
</tr>
<tr>
<td>Ocular graft versus host disease</td>
<td>2 (0.4)</td>
<td>8 (3.7)</td>
<td>14 (5.6)</td>
<td>24 (2.4)</td>
</tr>
<tr>
<td>None of the above</td>
<td>363 (68.0)</td>
<td>127 (58.3)</td>
<td>130 (52.0)</td>
<td>620 (61.9)</td>
</tr>
<tr>
<td>Eye-related procedures, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cataract surgery</td>
<td>65 (12.2)</td>
<td>33 (15.1)</td>
<td>43 (17.2)</td>
<td>141 (14.1)</td>
</tr>
<tr>
<td>Refractive procedures and surgeries</td>
<td>26 (4.9)</td>
<td>14 (6.4)</td>
<td>22 (8.8)</td>
<td>62 (6.2)</td>
</tr>
<tr>
<td>Glaucoma surgery</td>
<td>16 (3.0)</td>
<td>12 (5.5)</td>
<td>20 (8.0)</td>
<td>48 (4.8)</td>
</tr>
<tr>
<td>None of the above</td>
<td>438 (82.0)</td>
<td>168 (77.1)</td>
<td>186 (74.4)</td>
<td>792 (79.0)</td>
</tr>
</tbody>
</table>

DED, dry eye disease; EDS, Eye Dryness Score; HCP, healthcare professional.
severe problems or being unable to move vs 23% of participants without DED). In addition, more problems with self-care (19% vs 8%), usual activities (38% vs 21%) and anxiety/depression (47% vs 32%) were reported in participants with DED than in participants without DED. This difference could be explained by the presence of DED; however, the higher prevalence of comorbidities in participants with DED could be a contributing factor. The
ocular comorbidity with the greatest difference between participants with and without DED was pain/discomfort: 72% of participants with DED reported some level of discomfort, while only 46% of participants without DED reported the same. Since the EQ-5D-5L is a measure of overall health status, it is very likely that participants with

Figure 4 OCI scores by severity group. Box for each score: IQR (Q1–Q3); +, mean; —, median; bottom and top bars, observed minimum and maximum values; ×, outliers (i.e., values that are outside the distance of 1.5 times the IQR from Q1 or Q3). EDS, Eye Dryness Score; OCI, Ocular Comfort Index.

Figure 5 VFQ-28R scores by severity group. Box for each score: IQR (Q1–Q3); +, mean; —, median; bottom and top bars, observed minimum and maximum values; ×, outliers (i.e., values that are outside the distance of 1.5 times the IQR from Q1 or Q3). EDS, Eye Dryness Score; Q, quarter; VFQ-28R, 28-item revised Visual Function Questionnaire.
comorbidities had lower scores (indicating lower health status) than participants without comorbidities. More sophisticated analyses would be required to answer this question. Overall health status (EQ-5D index score) was lower for participants with DED, indicating that this cohort with DED experienced reduced health status compared with those without DED.

Due to the sampling techniques used to enrol participants into the study, baseline characteristics of participants with and without DED were comparable on average. There were similar proportions of men and women, similar mean ages, digital screen use and activities such as reading, irrespective of disease status. However, other environmental factors were more frequently reported by participants with DED (air conditioning, forced air, low humidity and polluted air); these factors could contribute to the development of DED or could be noticed more by those with DED. Comorbidities were more prevalent in participants with DED than in those without (eg, arthritis, 38% vs 21%; hearing loss, 24% vs 9%). While causal associations cannot be drawn in a cross-sectional study, the presence of DED appeared to impact negatively on participants’ health-related and vision-related QoL.

Participants were categorised into groups 1–3 according to their 24-hour EDS single-item VAS (range, 0–100), with a higher score indicating a higher severity. Those in group 3 with the highest EDS VAS had the highest level of discomfort for all symptoms (eg, eye discomfort, tired eyes, itching eyes) related to DED and a greater impact on activities and socioemotional functioning (assessed by VFQ-28R). Similarly, the mean OCI score also increased in participants with DED as severity increased, with greater discomfort observed in the eyes of participants with a higher EDS. A similar trend was seen for other questionnaires. Participants with higher severity as assessed by EDS had a higher severity and frequency of symptoms as assessed by mean DEQ-5 scores. Participants with higher severity also had higher mean SPEED scores, indicating more frequent and/or more severe symptoms.

Mean scores for WPAI globally increased as the severity increased. This reflects a higher impact of DED on activity impairment as the EDS increased. For impairment while working, overall work impairment and time missed from work, the mean scores were slightly lower in severity group 3 versus group 2. This could be due to a limitation in the definition of the EDS severity categories, or there is only a slight association between DED and work productivity and activity impairment.

The results of this study suggest the usefulness of the EDS as a single score to assess the severity of dry eye symptoms in individuals with DED. Compared with other common DED symptom scales, a higher EDS (indicating

![Figure 6](http://bmjopen.bmj.com/) Description of answers to EQ-5D-5L items by severity group. Percentages not shown on figure were <5%. EDS, Eye Dryness Score; EQ-5D-5L, EuroQol 5 dimensions 5 levels.
more discomfort) was associated with worse symptoms on the OCI, DEQ-5 and SPEED. Additional analyses should be performed to confirm the reliability of the EDS to discriminate between different levels of DED severity. No inferential statistics were performed due to the nature of this study; hence, future studies could benefit from applying statistical tests to validate the associations and strengths of associations of the variables studied.

Strengths and limitations of this study
This comprehensive study is the largest DED survey completed in the UK assessing differences in health-related and vision-related QoL among participants with and without DED. However, the findings from this study have some limitations. First, this study was a descriptive analysis based on a single-item tool to assess severity of DED symptoms (eye dryness), and this is currently undergoing psychometric validation. Second, since this was an internet-based survey, individuals without access to the internet did not have the opportunity to participate in the study. Third, DED was self-reported by participants based on their symptoms, and this can be unreliable and may result in misclassification. Fourth, DED was diagnosed by a healthcare professional in approximately 50% of the participants included in DED groups 1 and 2, and 75% in group 3, and only half of the healthcare professionals were ophthalmologists, which may impact the accuracy of DED diagnosis and classification. Lastly, as this was a cross-sectional study, we could not assess whether the vision-related QoL was low prior to a diagnosis of DED and whether vision-related QoL changed over time.

CONCLUSIONS
This analysis provides useful information regarding participants’ perspectives on the burden of DED in the UK. DED symptoms were associated with negative impacts to socioemotional functioning, vision-related QoL function, daily activities and work productivity. Participants with worse DED symptoms had a greater decline in socioemotional functioning, vision-related QoL, daily activities and work productivity. Symptom severity determined by EDS was associated with severity on common DED instruments, such as OCI, DEQ-5, and SPEED, suggesting that the EDS may be a useful single-item questionnaire for assessing severity of symptoms in individuals with DED.

Figure 7  WPAI subscale scores by severity group. Box for each score: IQR (Q1–Q3); +, mean; —, median; bottom and top bars, observed minimum and maximum values; ×, outliers (i.e., values that are outside the distance of 1.5 times the IQR from Q1 or Q3). EDS, Eye Dryness Score; Q, quarter; WPAI, Work Productivity and Activity Impairment.

<table>
<thead>
<tr>
<th>Group 1 (EDS&lt;40)</th>
<th>Group 2 (40≤EDS&lt;60)</th>
<th>Group 3 (EDS≥60)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD)</td>
<td>Percent activity impairment due to problem</td>
<td>Percent impairment while working due to problem</td>
</tr>
<tr>
<td>15.2 (20.3)</td>
<td>25.8 (24.1)</td>
<td>31.6 (26.7)</td>
</tr>
</tbody>
</table>

WPAI score

1Clinical Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
2Eye Unit, Southampton General Hospital, University Hospitals Southampton NHS Foundation Trust, Southampton, UK
3Global Evidence and Outcomes, Takeda, Lexington, Massachusetts, USA
4Department of Interdisciplinary Health Sciences, College of Allied Health Sciences, Augusta University, Augusta, Georgia, USA
5Patient Centered Outcomes, Modus Outcomes, Lyon, France
6Patient Centered Outcomes, Modus Outcomes, Cambridge, Massachusetts, USA
7Cornea and Refractive Surgery Service, Massachusetts Eye and Ear, Boston, Massachusetts, USA
8Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA
Acknowledgements

We acknowledge İpek Özer Stillman, from Takeda, for her assistance with survey conceptualisation and development, interpretation of the data and study operations; and Patrick Marquis from Modus Outcomes for his assistance with survey conceptualisation and development. We thank Lisa O’Brien, PharmD, of Excel Scientific Solutions, who provided medical writing assistance, supported by Takeda and Novartis.

Contributors

All authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: PH, CS, CJ, JTM, JM and RD. Acquisition, analysis or interpretation of data: PH, CS, CJ, JTM, JM and RD. Drafting of the manuscript and review: PH, CS, CJ, JTM, JM and RD. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding

This study was supported by Takeda (Award/ Grant number: N/A) and Novartis (Award/ Grant number: N/A).

Competing interests

PH is a consultant for Dompé, Santen and Shire*. CS is an employee of and owns stock/stock options in Takeda. CJ is an employee of and owns stock/stock options in Takeda. JM is an employee of Modus Outcomes and has been a consultant for Shire* on this study. JTM is an employee of Modus Outcomes and has been a consultant for Shire* on this study. RD is a consultant for Aldeya, Dompé, GSK, Kala and Shire*, holds equity in Aramis Biosciences and Claris Biotherapeutics and reports receiving grant support from Allegen and the National Eye Institute. *Takeda company.

Patient and public involvement

Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

Patient consent for publication

Not required.

Ethics approval

The study was approved by the New England Independent Review Board.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data availability statement

Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information. We confirm that the data generated by our research supports our current article. We confirm that we have included all our generated data in this manuscript. Novartis is committed to sharing with qualified external researchers, access to patient level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided are anonymised to respect the privacy of patients who have participated in the online surveys in line with applicable laws and regulations. The authors confirm that they had no special access or privileges that others researchers would not have. Unfortunately, we are unable to provide copies of the survey as the questions asked were from copyrighted questionnaires.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Parvez Hossain http://orcid.org/0000-0002-3131-2395

REFERENCES

7 The management of dry eye. Drug Ther Bull 2016;54:9–12.